000155542 001__ 155542
000155542 005__ 20240229115142.0
000155542 0247_ $$2pmc$$apmc:PMC8789696
000155542 0247_ $$2doi$$a10.1007/s10072-021-05365-1
000155542 0247_ $$2pmid$$apmid:34109514
000155542 0247_ $$2ISSN$$a0392-0461
000155542 0247_ $$2ISSN$$a1126-5442
000155542 0247_ $$2ISSN$$a1590-1874
000155542 0247_ $$2ISSN$$a1590-3478
000155542 0247_ $$2altmetric$$aaltmetric:107454889
000155542 037__ $$aDZNE-2021-00720
000155542 041__ $$aEnglish
000155542 082__ $$a610
000155542 1001_ $$0P:(DE-2719)9000916$$aBecker, Sara$$b0$$eFirst author$$udzne
000155542 245__ $$aQuantifying activities of daily living impairment in Parkinson's disease using the Functional Activities Questionnaire.
000155542 260__ $$aMilano$$bSpringer$$c2022
000155542 3367_ $$2DRIVER$$aarticle
000155542 3367_ $$2DataCite$$aOutput Types/Journal article
000155542 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1709128338_1144
000155542 3367_ $$2BibTeX$$aARTICLE
000155542 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155542 3367_ $$00$$2EndNote$$aJournal Article
000155542 520__ $$aCognitive-driven activity of daily living (ADL) impairment in Parkinson's disease (PD) is increasingly discussed as prodromal marker for dementia. Diagnostic properties of assessments for this specific ADL impairment are sparsely investigated in PD. The ability of the Functional Activities Questionnaire (FAQ) for differentiating between PD patients with normal cognition and with mild cognitive impairment (PD-MCI), according to informant and self-reports, was examined. Global cognitive function in groups with and without mild ADL impairment was compared according to different cut-offs.Multicenter data of 589 patients of an international cohort (CENTRE-PD) were analyzed. Analyses were run separately for informant-rated and self-rated FAQ. Receiver operating characteristic (ROC) analysis was conducted to define the optimal FAQ cut-off for PD-MCI (≥ 1), and groups were additionally split according to reported FAQ cut-offs for PD-MCI in the literature (≥ 3, ≥ 5). Binary logistic regressions examined the effect of the Montreal Cognitive Assessment (MoCA) score in PD patients with and without mild ADL impairment.Two hundred and twenty-five (38.2%) patients were classified as PD-MCI. For all three cut-off values, sensitivity was moderate to low (< 0.55), but specificity was moderately high (> 0.54) with a tendency of higher values for self-reported deficits. For the self-report, the cut-off ≥ 3 showed a significant effect of the MoCA (B = - 0.31, p = 0.003), where FAQ ≥ 3 patients had worse cognition. No effect for group differences based on informant ratings was detected.Our data argue that self-reported ADL impairments assessed by the FAQ show a relation to the severity of cognitive impairment in PD.
000155542 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000155542 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x1
000155542 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x2
000155542 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000155542 650_7 $$2Other$$aCognitive dysfunction
000155542 650_7 $$2Other$$aCohort studies
000155542 650_7 $$2Other$$aMild cognitive impairment
000155542 650_7 $$2Other$$aNeuropsychological tests
000155542 650_2 $$2MeSH$$aActivities of Daily Living
000155542 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000155542 650_2 $$2MeSH$$aCognitive Dysfunction: etiology
000155542 650_2 $$2MeSH$$aHumans
000155542 650_2 $$2MeSH$$aMental Status and Dementia Tests
000155542 650_2 $$2MeSH$$aNeuropsychological Tests
000155542 650_2 $$2MeSH$$aParkinson Disease: complications
000155542 650_2 $$2MeSH$$aParkinson Disease: diagnosis
000155542 650_2 $$2MeSH$$aSurveys and Questionnaires
000155542 7001_ $$aPauly, Claire$$b1
000155542 7001_ $$aLawton, Michael$$b2
000155542 7001_ $$aHipp, Geraldine$$b3
000155542 7001_ $$aBowring, Francesca$$b4
000155542 7001_ $$0P:(DE-2719)2811919$$aSulzer, Patricia$$b5$$udzne
000155542 7001_ $$aHu, Michele$$b6
000155542 7001_ $$0P:(DE-2719)2811170$$aKrüger, Rejko$$b7$$udzne
000155542 7001_ $$0P:(DE-2719)2320009$$aGasser, Thomas$$b8$$udzne
000155542 7001_ $$0P:(DE-2719)2109499$$aLiepelt-Scarfone, Inga$$b9$$eLast author$$udzne
000155542 773__ $$0PERI:(DE-600)1481772-X$$a10.1007/s10072-021-05365-1$$n2$$p1047-1054$$tNeurological sciences$$v43$$x1590-3478$$y2022
000155542 8564_ $$uhttps://link.springer.com/article/10.1007%2Fs10072-021-05365-1
000155542 8564_ $$uhttps://pub.dzne.de/record/155542/files/19564.pdf$$yOpenAccess
000155542 8564_ $$uhttps://pub.dzne.de/record/155542/files/19564.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000155542 909CO $$ooai:pub.dzne.de:155542$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000155542 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000916$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000155542 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811919$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000155542 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811170$$aExternal Institute$$b7$$kExtern
000155542 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2320009$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000155542 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2109499$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000155542 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000155542 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x1
000155542 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x2
000155542 9130_ $$0G:(DE-HGF)POF3-345$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vPopulation Studies and Genetics$$x0
000155542 9130_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x1
000155542 9130_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x2
000155542 9141_ $$y2022
000155542 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000155542 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-29
000155542 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-29
000155542 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-29
000155542 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000155542 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-29
000155542 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROL SCI : 2021$$d2022-11-29
000155542 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000155542 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-29$$wger
000155542 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000155542 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-29
000155542 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-29
000155542 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-29
000155542 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000155542 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-29
000155542 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-29$$wger
000155542 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-29
000155542 9201_ $$0I:(DE-2719)1013024$$kAG Latz ; AG Latz$$lInnate Immunity in Neurodegeneration$$x0
000155542 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x1
000155542 9201_ $$0I:(DE-2719)1240005$$kCore ICRU$$lCore ICRU$$x2
000155542 9201_ $$0I:(DE-2719)1210002$$kAG Heutink$$lGenome Biology of Neurodegenerative Diseases$$x3
000155542 980__ $$ajournal
000155542 980__ $$aVDB
000155542 980__ $$aUNRESTRICTED
000155542 980__ $$aI:(DE-2719)1013024
000155542 980__ $$aI:(DE-2719)1210000
000155542 980__ $$aI:(DE-2719)1240005
000155542 980__ $$aI:(DE-2719)1210002
000155542 9801_ $$aFullTexts